Pave Finance Raises $15.0M Series A

Tabby

Helping users keep tabs on the people that matter most

Speclipse, Inc.

Speclipse, Inc., is the medical device developer of the world’s first cancer diagnostic solution based on laser-induced plasma spectroscopy (LIPS) and artificial intelligence (AI) technology. Our core technology, Spectra-Scope®, embodies a real-time, non-invasive, in-vivo diagnosis of skin cancers without compromising efficacy and accuracy while preventing unnecessary biopsies. We are committed to providing innovative medical technology to assist in challenging diagnosis cases—and it is our mission to continue to improve our technology so physicians can spend more time focusing on their patients and making accurate diagnoses.

Humanos

Humanos is building the Risk Network for AI. As AI agents begin operating across organizations, companies need infrastructure to reduce the risk of operating AI, while insurers, compliance teams, auditors, and other risk stakeholders need a way to independently evaluate that risk. Through a single Risk API, Humanos unifies identity, authorization, guardrails, enforcement, and Risk Intelligence. Before an AI agent acts, systems can verify who it is, who it represents, what it is authorized to do, collect missing authorization when needed, and enforce the required guardrails. Every interaction generates runtime evidence that the Risk Network turns into independently verifiable attestations, allowing risk stakeholders to evaluate AI operations without accessing the underlying operational data. One Risk Network. One Risk API. Infrastructure for reducing and evaluating AI risk.